Ana Serrano-Combarro, MD

Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander
Santander, Spain

Third year resident of Rheumatology in Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Presentation(s):

0737: Effectiveness and Safety of Janus Kinase Inhibitors in Giant Cell Arteritis. Real-World Clinical Practice Study and Literature Review

Sunday, October 26, 2025
10:30 AM - 12:30 PM Central Time
Disclosure information not submitted.
0736: Effectiveness of Tocilizumab in strokes in patients with giant cell arteritis. Spanish multicenter study of clinical practice

Sunday, October 26, 2025
10:30 AM - 12:30 PM Central Time
Disclosure information not submitted.
1258: Upadacitinib in the treatment of Rheumatoid Arthritis - Interstitial Lung Disease. National multicenter study of 25 patients in clinical practice.

Monday, October 27, 2025
10:30 AM - 12:30 PM Central Time
Disclosure information not submitted.
2016: Effectiveness of Nintedanib combined with different DMARDs in joint and pulmonary domains of Rheumatoid Arthritis - Interstitial Lung Disease. National multicenter study of 74 patients

Tuesday, October 28, 2025
10:30 AM - 12:30 PM Central Time
Disclosure information not submitted.
2229: National Multicenter study of Baricitinib in Rheumatoid Arthritis - Interstitial Lung Disease: effectiveness and progressive lung disease

Tuesday, October 28, 2025
10:30 AM - 12:30 PM Central Time
Disclosure information not submitted.
2265: Progressive Interstitial Lung Disease associated to Rheumatoid Arthritis despite Abatacept therapy. Data from a large national multicenter cohort of 526 patients

Tuesday, October 28, 2025
10:30 AM - 12:30 PM Central Time
Disclosure information not submitted.